ABEONA THERAPEUTICS INC.
About ABEONA THERAPEUTICS INC.
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.8M
- Net income
- $71.2M
- Total assets
- $219.6M
- Market cap
- $311.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $64.2M
- Operating income
- -$64.2M
- Net income
- -$63.7M
- EPS (basic)
- $-1.55
- EPS (diluted)
- $-1.55
Balance sheet
- Total assets
- $108.9M
- Current assets
- $100.9M
- Total liabilities
- $64.9M
- Current liabilities
- $16.6M
- Shareholders’ equity
- $44.0M
Cash flow
- Operating cash flow
- -$56.0M
- Investing cash flow
- -$39.2M
- Financing cash flow
- $104.1M
- Net cash flow
- $8.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $311.2M
- EPS (diluted)
- $-1.55
- Shares outstanding
- 57.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 19, 1980
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $71.2M in FY2025.
- Trading 26% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review ABEONA THERAPEUTICS INC..
Write a review
News about ABEONA THERAPEUTICS INC.
News & sentiment via Polygon.io
